Investments in Innovative Methods: Rapid Sterility Testing

At the turn of the century, viral manufacturers were facing major headwinds, and the sector was in a rut. Part of the problem was the inability to get enough clinical grade DNA, quickly enough, at the right price point for them to be able to progress through clinical trials.

If you would you like to discuss this research piece get in touch

Contact us Share article